NCT03202784View on ClinicalTrials.gov

A Relative Bioavailability Study of Two Formulations of BCX7353

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

August 1, 2017

Study Completion Date

September 30, 2017

Conditions
Hereditary Angioedema
Interventions
DRUG

BCX7353

BCX7353

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY